. Author manuscript; available in PMC: 2019 Aug 20.

Published in final edited form as: J Control Release. 2017 Aug 26;264:306–332. doi: 10.1016/j.jconrel.2017.08.033

Table 5. Basic properties and characteristics of SLNs & NLCs used for the treatment of Alzheimer’s disease.

Type of carrier	Solid lipid	Liquid lipid	Emulsifiers/ stabilizers/ surfactants	Preparation method	T (°C)	Size (nm)	Zeta (mV)	EE (%)	DL (%)	Therapeutic molecule	Targeting moiety	In Vitro	In vivo	Ref
NLC	CP	Miglyol^® 812	Soybean phosphatidylcholine, Solutol® HS15	EUT-HPH	52	120	-22.93 ±0.91	89.18 ±0.28	1.46±0.05	HupA	N/A	N/A	N/A	[155]
MEM	-	Capmul^® MCM	Transcutol^® P, Tween^® 80	MEM	25	148.3 ± 5.1	–4 ± 7.83	98.82 ± 1.12	N/A	HupA	N/A	N/A	Male Swiss Albino mice (25–30 g, 4–6 weeks old)	[156]
SLN	GMS	-			60-63	119.1 ± 6.9	–20 ± 5.81	98.66 ± 1.67
NLC	GMS	Capmul^® MCM			60-63	137.1 ± 10.4	–17.5 ± 7.16	99.38 ± 1.08
SLN	Compritol^® ATO 888	-	Tween^® 80	MEM	70-75	152 to 4620	-20 to - 5	85.73	N/A	QRT	N/A	N/A	Male Wistar rats (180–200 g)	[157]
Liposo mes	Cholesterol, Sphingomyelin, & gangliosides, Sm, PC, PE, Chol, PG, PA, CL	-	-	Extrusion	40	141-178	-11 to - 49	N/A	N/A	N/A	PA	N/A	N/A	[158]
SLN	StA, PA	-	Phospholipon 90G, sodium taurocholate	MEM	70	46-76	-39 to -43	N/A	N/A	N/A	PA	N/A	N/A	[158]
SLN	GMS	-	Epikuron 200, Tween^® 80, 20	SDT	53±3	277.6 ± 2.4	–45.0 ± 1.7	68.2	N/A	PPR	N/A	N/A	Albino Wistar rats	[159]
NLC	PC, Cholesterol oleate	Glycerol triolate	-	SEvaM	40	75-163	-3.5 to -17	87-97	2.60 ± 0.17	CUR	Lf	BCEC	Sprague-Dawley rats (180–220g) and ICR mice (18–22g)	[160]
SLN	StA	-	Brij 78	SEvaM	75	160-195	-27 to - 35	88-92	12.5±1.30	LA-MEM	N/A	N2a NB, PHWB	N/A	[161]
SLN	Compritol^® ATO 888, Soy lecithin	-	Tween^® 80	MEM	82-85	40-70	N/A	75.97±2.91	97.57±1.63	Sesamol	N/A	N/A	Male Wistar rats (200–230 g, 3 months old, ICV-STZ)	[162]
SLN	StA, Lecithin	-	Taurocholate	HSHT	75	240.0 ± 4.79	–40.4 ± 2.54	86.29±3.42	71.10±3.12	Chrysin	N/A	N/A	Adult male Sprague–Dawley rats (250–300 g)	[163]